VLX

(2S)-2-[(4R)-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide

Find entries where: VLX

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	(2S)-2-[(4R)-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide
Identifiers	(2~{S})-2-[(4~{R})-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide
Formula	C₁₁ H₂₀ N₂ O₂
Molecular Weight	212.289
Type	NON-POLYMER
Isomeric SMILES	CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
InChI	InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
InChIKey	MSYKRHVOOPPJKU-BDAKNGLRSA-N

Chemical Details
Formal Charge	0
Atom Count	35
Chiral Atom Count	2
Bond Count	35
Aromatic Bond Count	0

Drug Info: DrugBank

DrugBank ID	DB05541
Name	Brivaracetam
Groups	investigational approved
Description	Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].
Synonyms	Brivaracetam
Brand Names	Brivlera Briviact
Indication	Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
Categories	Anticonvulsants Central Nervous System Agents Central Nervous System Depressants Cytochrome P-450 CYP2B6 Substrates Cytochrome P-450 CYP2C19 Substrates Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates Drugs that are Mainly Renally Excreted Epoxide Hydrolase Inhibitors Miscellaneous Anticonvulsants Nervous System Pyrrolidines
ATC-Code	N03AX23
CAS number	357336-20-0

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Synaptic vesicle glycoprotein 2A	MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFE...	unknown	unknown
Sodium channel protein	MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPK...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 2C19	MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV...	unknown	substrate
Cytochrome P450 2B6	MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRG...	unknown	substrate
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682